0I3Q Stock Overview
Engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Corcept Therapeutics Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$66.07 |
| 52 Week High | US$71.11 |
| 52 Week Low | US$20.92 |
| Beta | 0.55 |
| 1 Month Change | 31.97% |
| 3 Month Change | 38.72% |
| 1 Year Change | 208.02% |
| 3 Year Change | 250.32% |
| 5 Year Change | 418.55% |
| Change since IPO | 163.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0I3Q | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 9.0% | 2.9% | 2.0% |
| 1Y | 208.0% | 3.5% | 10.8% |
Return vs Industry: 0I3Q exceeded the UK Pharmaceuticals industry which returned 3.5% over the past year.
Return vs Market: 0I3Q exceeded the UK Market which returned 10.8% over the past year.
Price Volatility
| 0I3Q volatility | |
|---|---|
| 0I3Q Average Weekly Movement | 8.5% |
| Pharmaceuticals Industry Average Movement | 7.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.8% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0I3Q's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0I3Q's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 352 | Joseph Belanoff | www.corcept.com |
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing’s syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors.
Corcept Therapeutics Incorporated Fundamentals Summary
| 0I3Q fundamental statistics | |
|---|---|
| Market cap | US$7.01b |
| Earnings (TTM) | US$140.49m |
| Revenue (TTM) | US$628.56m |
49.9x
P/E Ratio11.2x
P/S RatioIs 0I3Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0I3Q income statement (TTM) | |
|---|---|
| Revenue | US$628.56m |
| Cost of Revenue | US$9.80m |
| Gross Profit | US$618.75m |
| Other Expenses | US$478.27m |
| Earnings | US$140.49m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.34 |
| Gross Margin | 98.44% |
| Net Profit Margin | 22.35% |
| Debt/Equity Ratio | 0% |
How did 0I3Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/01 03:33 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Corcept Therapeutics Incorporated is covered by 22 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| David Buck | B. Riley Securities, Inc. |
| Edward Nash | Canaccord Genuity |